Aurora Cannabis Provides Guidance for the Second Quarter of Fiscal 2019, Anticipating Net Revenues of $50M to $55M Company Provides Production Guidance and is Tracking to Achieve Positive EBITDA in Second Calendar Quarte

Aurora Cannabis Provides Guidance for

the Second Quarter of Fiscal 2019, Anticipating Net Revenues of $50M to $55M

Company Provides Production

Guidance and is Tracking to Achieve Positive EBITDA in Second Calendar Quarter 2019

EDMONTON, Jan. 8, 2019 /CNW/ - Aurora

Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (NYSE: ACB) (Frankfurt: 21P; WKN: A1C4WM) today provided

an expected revenue range for the second quarter of the Company's Fiscal 2019 ("Q2 2019"), the period ended December

31, 2018. Full results will be published on Monday, February 11, 2019 pre-market, followed by a conference call later that day,

details for which can be found at the end of this release.

Based on preliminary (unaudited) results, the

Company anticipates revenues for Q2 2019 of between $50 million and $55 million (net of excise taxes), compared to $11.7 million

for the same quarter in the prior year, and compared to $29.7 million for the previous quarter ended September 30, 2018 ("Q1

2019"). The results reflect an anticipated revenue growth rate in excess of 327% compared to Q2 2018 and in excess of 68%

compared to Q1 2019.

Revenue growth for the quarter was driven by

the Company's strong position in the adult consumer use market in Canada, continued shipments of medical cannabis to Aurora's expanding

base of approximately 71,000 patients in Canada, and relatively stable, supply restricted shipments, to its growing international

The Company continues to ramp its production

capacity up from 70,000 kg / annum as reported in November 2018, to approximately 100,000 kg / annum today and reaffirms its expectation

to achieve at least 150,000 kg / annum of production capacity within the first calendar quarter of 2019 ("Q3 2019").

Aurora defines production capacity as representing all planted rooms approved by Health Canada, factoring in anticipated harvests

at maturity annualized for the following twelve (12) month period, based on an average historical yield per plant.

Based on its current production capacity of

100,000 kg / annum and the Company's cultivation and harvest schedules, Aurora expects its production available for sale will be

approximately 25,000 kg equivalent of cannabis in the Company's Q4 2019, the period ending June 30, 2019, with continued production

volume increases in subsequent quarters. Aurora defines production available for sale as representing the Company's production

capacity harvested and processed into a final product for sale. Paired with strong current and future anticipated demand for the

Company's products across its different market segments, this is expected to result in continued strong revenue growth.

The market introduction of higher-margin products,

such as softgels, as well as its vape-ready CBD oil cartridge product Aurora Cloud, is expected to contribute to sustained strong

gross margins during fiscal 2019. Additionally, Aurora is looking forward to the upcoming finalization of the draft regulations

which will allow derivative, higher margin products such as vape pens, beverages, and edibles to be sold in the Canadian adult

use market during 2019.

Additionally, disciplined cost management is

anticipated to result in SG&A costs to be roughly consistent with the previous quarter, including a full quarter of costs related

to all integrated subsidiaries in MedReleaf, Anandia and Agropro. Consequently, management believes the combination of substantial

revenue growth and disciplined cost management positions the Company well to achieve sustained positive EBITDA beginning in Fiscal

Q4 2019 (Calendar Q2 2019).

The preliminary estimated financial results

and other data for the three months ended December 31, 2018 set forth above are subject to the completion of the Company's financial

closing procedures. These data have been prepared by, and is the responsibility of, the Company's management, and was approved

by management on January 7, 2019. Aurora's independent registered public accounting firm, KPMG LLP, has not audited, reviewed or

performed any procedures with respect to the accompanying preliminary financial results and other data, and accordingly does not

express an opinion or any other form of assurance with respect thereto. The Company currently expects that its final results of

operations and other data will be consistent with the estimates set forth above, but such estimates are preliminary and Aurora's

actual results of operations and other data could differ materially from these estimates due to the completion of its financial

closing procedures, final adjustments and other developments that may arise between now and the time such unaudited interim consolidated

financial statements for the three months ended December 31, 2018 are issued.

Management Commentary

"Aurora continues to execute effectively

across all market segments, as demonstrated by its revenue growth anticipated to exceed 68% as compared to last quarter, supported

by continued strong performance in the Canadian adult consumer use market," said Terry Booth, CEO of Aurora. "Our consistent

and high-quality production continues to significantly ramp up as expected, fueling even further growth. Going forward, we see

sustained strong demand from the adult usage market, as evidenced by public statements from the Canadian provinces, as well as

strong patient-driven demand for medical cannabis in Canada and abroad. These factors, together with our focus on disciplined management

of operating expenses, and our growing portfolio of higher margin products, put us in a position to rapidly achieve positive EBITDA

within the next two quarters."

The Company today released updated video of

its production facilities, including Aurora Sky, Aurora Eau, Aurora Vie, MedReleaf Bradford, Aurora Mountain, ICC Labs, and Agropro.

The footage demonstrates the technologically advanced nature of Aurora's diverse production assets, as well as the mature nature

of its operations. The video material may be viewed here: https://www.dropbox.com/s/o517edo5l9n2v5r/AURORA_FACILITIES_V06.mp4?dl=0

Second Quarter 2019 Conference Call

Aurora has scheduled its conference call to

discuss the results for its second quarter ended December 31, 2018, which will be released on Monday, February 11th,

2019 pre-market, The conference call will be hosted that day at 10:30 a.m. Eastern Time by Terry Booth, Chief Executive Officer,

Glen Ibbott, Chief Financial Officer, Cam Battley, Chief Corporate Officer, and Michael Singer, Chairman of the Board, followed

by a question and answer period.

Headquartered in Edmonton, Alberta, Canada

with funded capacity in excess of 500,000 kg per annum and sales and operations in 22 countries across five continents, Aurora

is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across

every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis

and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

Highly differentiated from its peers, Aurora

has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate

leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale

production of high quality product at low cost. Intended to be replicable and scalable globally, our production facilities are

designed to produce cannabis of significant scale, with high quality, industry-leading yields, and low per gram production costs.

Each of Aurora's facilities is built to meet EU GMP standards, and its first production facility, the recently acquired MedReleaf

Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland, have achieved this level of certification.

In addition to the Company's rapid organic

growth and strong execution on strategic M&A, which to date includes 15 wholly owned subsidiary companies - MedReleaf,

CanvasRx, Peloton Pharmaceutical, Aurora Deutschland , H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses,

CanniMed Therapeutics, Anandia Labs, HotHouse Consulting, MED Colombia, Agropro, Borela, and ICC Labs - Aurora is distinguished

by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic

partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV:

HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Capcium Inc. (private),

Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), and Alcanna Inc. (TSX: CLIQ).

Aurora's Common Shares trade on the TSX and

NYSE under the symbol "ACB", and are a constituent of the S&P/TSX Composite Index.

For more information about Aurora, please visit

our investor website, investor.auroramj.com

Aurora Cannabis Inc.

Forward looking statements

This news release makes reference to certain

non-IFRS measures, including certain industry metrics. These metrics and measures are not recognized measures under IFRS do not

have meanings prescribed under IFRS and are as a result unlikely to be comparable to similar measures presented by other companies.

These measures are provided as information complimentary to those IFRS measures by providing a further understanding of our operating

results from the perspective of management. As such, these measures should not be considered in isolation or in lieu of review

of our financial information reported under IFRS. This news release uses non-IFRS measures including "EBITDA", "production